University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
CSE Journal Articles

Computer Science and Engineering, Department of

2018

Expression of the microRNA-143/145 cluster is
decreased in hepatitis B virus-associated
hepatocellular carcinoma and may serve as a
biomarker for tumorigenesis in patients with
chronic hepatitis B
Qi Zhao
Shandong University

Xiangfei Sun
Shandong University

Chao Liu
University of Nebraska-Lincoln

Tao Li
Shandong University

Juan Cui
University of Nebraska-Lincoln, jcui@unl.edu

Zhao, Qi; Sun, Xiangfei; Liu, Chao; Li, Tao; Cui, Juan; and Qin, Chengyong, "Expression of the microRNA-143/145 cluster is
decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with
chronic hepatitis B" (2018). CSE Journal Articles. 156.
http://digitalcommons.unl.edu/csearticles/156

This Article is brought to you for free and open access by the Computer Science and Engineering, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in CSE Journal Articles by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.

See next page for additional authors

Follow this and additional works at: http://digitalcommons.unl.edu/csearticles
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons,
Hepatology Commons, Numerical Analysis and Scientific Computing Commons, and the Other
Computer Sciences Commons

Authors

Qi Zhao, Xiangfei Sun, Chao Liu, Tao Li, Juan Cui, and Chengyong Qin

This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/csearticles/156

ONCOLOGY LETTERS 15: 6115-6122, 2018

Expression of the microRNA-143/145 cluster is decreased
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Abstract. The aims of the present study were to identify the
expression profile of microRNA (miR)‑143/145 in hepatitis B
virus (HBV)‑associated hepatocellular carcinoma (HCC),
explore its association with prognosis and investigate whether the
serum miR‑143/145 expression levels may serve as a diagnostic
indicator of HBV‑associated HCC. The microRNA (miRNA)
chromatin immunoprecipitation dataset was obtained from
The Cancer Genome Atlas (TCGA) and the Gene Expression
Omnibus databases, and analyzed using the Wilcoxon
signed‑rank test. It was observed that the expression of miR‑143
and miR‑145 was decreased 1.5‑fold in HBV‑associated HCC
samples compared with non‑tumor tissue in the TCGA and
the GSE22058 datasets (P<0.01). Using the reverse transcription‑quantitative polymerase chain reaction, it was further
confirmed that miR‑143/145 and their host gene MIR143HG
were downregulated in HBV‑associated HCC tissues compared
with corresponding distal non‑tumor tissues. The lower level
of miR‑143 and miR‑145 expression was associated with tumor
differentiation, and may thus be responsible for a poor prognosis
of patients with HBV‑associated HCC. The receiver‑operating
characteristic (ROC) curves were used to explore the potential
value of miR‑143 and miR‑145 as biomarkers for predicting
HBV‑associated HCC tumorigenesis. In serum, miR‑143/145
were identified to be significantly decreased in patients with
HBV‑associated HCC compared with negative control patients,
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and their associated areas under the ROC curves were calculated
at 0.813 and 0.852 (P<0.05), with each having a sensitivity
and a specificity close to 0.80. These results indicated that the
decreased expression of the miR‑143/145 cluster and their host
gene MIR143HG in HBV‑associated HCC tissue was associated
with prognosis, and each of these miRNAs may serve as a valuable diagnostic biomarker for predicting HBV‑associated HCC
tumorigenesis.
Introduction
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer mortality worldwide. A variety of risk factors
may promote HCC genesis, including hepatitis B virus (HBV)
infection, hepatitis C virus infection, heavy alcohol consumption
and non‑alcoholic fatty liver disease (1,2). In the last decade, a
marked increase in the incidence of HBV‑associated HCC has
been observed, particularly in China. Since the prognosis of
patients with HCC is markedly dependent on the stage of the
disease, strategies for early detection of HCC have been investigated.
MicroRNAs (miRNAs) are short 20‑22‑nucleotide single‑
stranded RNA molecules, which have been associated with
epigenetic regulation in a range of diseases, including tumorigenesis (3‑5). miRNAs regulate gene expression by altering
the stability or the translational efficiency of target mRNAs.
A previous study demonstrated that miRNAs are detectable
and stable in serum (6); therefore, research has focused on the
possibility of using miRNAs as biomarkers for predicting the
diagnosis and prognosis of several diseases.
Two human miRNAs, miRNA‑143 (miR‑143) and miR‑145
have been investigated as biomarkers for several types of
cancer. miR‑143 and miR‑145 are stably expressed homologous
miRNAs located within the same host gene, MIR143HG (7).
The first study to examine the miR‑143/145 cluster focused on
HBV‑associated HCC. This study demonstrated that miR‑143
expression was increased in HBV‑associated HCC tumors and
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was associated with invasive and metastatic behavior of liver
tumor cells (8). Conversely, evaluation of the miR‑143/145 cluster
expression in other types of tumor, including colonic carcinoma,
pulmonary carcinoma, esophageal carcinoma and prostatic
carcinoma (9‑12), demonstrated that the miR‑143/145 cluster
expression level was decreased. This raises the question of why
the miR‑143/145 cluster is overexpressed in HBV‑associated
HCC‑derived tumors, but is underexpressed in other types of
tumor. However, previous studies have produced contradictory
results (13‑15), demonstrating that the miR‑143/145 expression
level was decreased in HBV‑associated HCC‑derived tumors
which contradicts the results of another previously mentioned
study (8). Furthermore, a previous study demonstrated that the
expression of the miR‑143/145 cluster was negligible in liver
tissues, including normal liver tissue or HBV‑associated HCC
tissue (7). This controversy was investigated further in the
present study.
In the present study, the expression profile of miR‑143
and miR‑145 in HBV‑associated HCC tissues and non‑tumor
tissues was investigated using chromatin immunoprecipitation
(ChIP) data from The Cancer Genome Atlas (TCGA) and the
Gene Expression Omnibus (GEO) datasets. Their expression
in HBV‑associated HCC tissue was also validated using the
reverse transcription‑quantitative polymerase chain reaction
(RT‑qPCR). The association between miR‑143/145 expression and specific clinical features including tumorigenesis,
tumor progression and prognosis was subsequently examined.
Finally, the serum expression of miR‑143 and miR‑145 was
determined to evaluate their potential clinical applications.
The receiver‑operating characteristic (ROC) curves were used
to explore their potential value as biomarkers for predicting
HBV‑associated HCC tumorigenesis.

were obtained from 85 patients with HBV‑associated HCC
from February 2012 to January 2013 at the Provincial Hospital
Affiliated to Shandong University (Jinan, China). The mean
patient age was 53.2±9.3 years (range, 25‑75 years), and 70.6%
of the patients were male. Ten tissue samples from patients with
hepatic hemangioma and 5 ml venous peripheral blood from
50 patients with chronic hepatitis B were collected as negative
controls. All tissue samples were histologically confirmed by
a pathologist using hematoxylin and eosin staining of cryosectioned specimens. The criteria used for distal non‑cancerous
liver tissues were absence of tumor cells and 5 cm distance
from the tumors. Blood samples were collected in Vacutainer®
serum separating tubes (BD Biosciences, Franklin Lakes, NJ,
USA). Serum was collected by centrifugation at 2,000 x g
for 10 min at 4˚C after allowing the blood to clot for 30 min.
Written informed consent was obtained from each patient, and
the consent procedure and study protocol were approved by
the Medical Institutional Ethical Committee of the Provincial
Hospital Affiliated to Shandong University.
Clinical features. Clinical features including histological
grade, metastasis, cirrhosis, and complete tumor capsule were
reported by pathologists following post‑surgical pathological
examination of HBV‑associated HCC samples.

Identification of differentially expressed miRNAs. For each
dataset, the Wilcoxon signed‑rank test was used to identify the
differentially expressed genes between tumor and non‑tumor
samples. The null hypothesis was that a gene was not differentially expressed between the two groups and rejection of this
hypothesis indicated that the gene was differentially expressed.
A miRNA was considered upregulated if P<0.01 and its fold
increase was ≥1.5. Downregulated miRNAs were similarly
defined.

miRNA/mRNA extraction and RT‑qPCR. The mRNAiso Plus
and microRNAiso Plus kits (Takara Biotechnology Co., Ltd.,
Dalian, China) were used for mRNA and miRNA extraction from liver tissue, respectively. The MiRCURY RNA kit
(Exiqon A/S, Vedbaek, Denmark), a specific kit for extracting
microRNA from the serum, was used to extract miRNA from
serum samples in order to guarantee the validation of the
concentration of microRNAs. The PrimeScript™ RT Reagent
kit and SYBR Premix Ex Taq (Takara Biotechnology Co.,
Ltd.) were used for first‑strand cDNA synthesis and RT‑qPCR,
respectively, according to the manufacturer's protocols.
β‑actin was used for mRNA normalization. β‑actin forward,
3'‑GGCACCACACCTTCTACAATG‑5' and reverse, 3'‑TAG
CACAGCCTGGATAGCA AC‑5'. RT‑qPCR for microRNAs
was performed on a 480 PCR system (Roche Diagnostics,
Basel, Switzerland), at 95˚C for 1 min followed by 45 cycles
of 95˚C for 5 sec, 65˚C for 30 sec and 72˚C for 30 sec. The
expression of miRNAs in serum samples was calculated using
the comparison 2‑∆∆Cq method (18) relative to RNU6B (U6).
The following specific forward and reverse primers were used
in pairs when amplifying miRNA: miR‑143 forward, 3'‑GTG
CAGT GCT GCATCT CTG GT‑5'; 143HG forward, 3'‑GTG
AAGG CAGAGGACACACCT‑5' and reverse, 3'‑AAAACC
GTGCATT TGG CTG ‑5'. The forward primers for miR‑145
and U6 and the reverse primers for all microRNAs were
purchased as finished products from Takara Biotechnology
Co., Ltd. (cat. nos. SJD14025 and SJD14078). PCR product
sizes were validated by electrophoresis using 2% agarose and
12% polyacrylamide, 8 M urea gel (19). All kits were used
according to the manufacturer's protocol. All the experiments
were performed >3 times generating similar results and error
bars represent the standard error of the mean of 6 repeats.

Clinical samples. HBV‑associated HCC tissues, matched distal
non‑cancerous liver tissues and 5 ml venous peripheral blood

Statistical analysis. SPSS software (version 16.0; SPSS, Inc.,
Chicago, IL, USA) was used to analyze the data. Comparisons

Materials and methods
TCGA miRNA dataset. The miRNA expression profile of
372 patients with HCC and 50 non‑tumor distal liver samples
was obtained from the TCGA dataset (cancergenome.nih.gov).
According to the clinical information, 102 patients with HBV
infection were selected as negative control.
GEO dataset. The GEO database (16) was accessed to obtain
the normalized miRNA microarray dataset GSE22058 (www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22058), which
represents the miRNA expression profile of tumor and adjacent
non‑tumor tissues of 96 patients with HCC. From these patients,
~88% were confirmed positive for the HBV antigen (17).
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Figure 1. hsa‑143/145 expression analysis using miRNA ChIP data from the GEO and the TCGA databases. (A) The expression of miR‑145 was decreased
in the HBV‑associated HCC samples (n=96, 88% positive for HBV antigen) compared with the matched adjacent non‑tumor tissues (n=96) in the GSE22058
database (**P<0.001, Wilcoxon signed‑rank test). (B) The expression of miR‑145 was significantly decreased in the HBV‑associated HCC samples (n=372)
compared with the non‑tumor liver samples (n=50) in the TCGA dataset (**P<0.001; Wilcoxon signed‑rank test). (C) The expression of miR‑143 was decreased
in the HBV‑associated HCC samples (n=96, 88% positive for HBV antigen) compared with the matched adjacent non‑tumor tissues (n=96) in the GSE22058
database (**P<0.001, Wilcoxon signed‑rank test). (D) The expression of miR‑143 was decreased in the HBV‑associated HCC samples (n=102) compared with
the non‑tumor liver samples (n=50) in the TCGA dataset (P=0.004, Wilcoxon signed‑rank test). *P<0.01. hsa, Homo sapiens; miRNA/miR, microRNA; GEO,
Gene Expression Omnibus; TCGA, The Cancer Genome Atlas; ChIP, chromatin immunoprecipitation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.

between matched HBV‑associated HCC tissue and non‑tumor
tissue was performed by paired Student's t‑test and Wilcoxon
signed‑rank test. Unmatched continuous data were compared
using an independent two‑tailed t‑test. The association
between the expression of miR‑143, miR‑145 and MIR143HG
is analyzed by Pearson correlation in HBV‑associated HCC
tissues. The diagnostic value of serum miR‑143/145 expression
was assessed by the area under the ROC curves (AUC). The
diagnostic accuracy was assessed by sensitivity, specificity,
positive predictive value and negative predictive value. P<0.05
was considered to indicate a statistically significant difference.
Results
miRNA expression profile analysis in patients with
HBV‑associated HCC reveals that miR‑143 and miR‑145
are among the 63 differentially expressed miRNAs. The
HBV‑associated HCC and non‑tumor tissue miRNA ChIP data
were obtained from the TCGA and the GEO datasets (16,17).
It was identified that in the HBV‑associated HCC samples,
24 miRNAs were increased >1.5‑fold (P<0.01) and 39 miRNAs
were decreased >1.5‑fold compared with the matched adjacent
non‑tumor samples. miR‑143 and miR‑145 were among the
39 significantly decreased miRNAs in the HBV‑associated
HCC samples (Fig. 1). The expression of miR‑145 was significantly downregulated in the HBV‑associated HCC samples
compared with the non‑tumor samples from the GSE22058
(P<0.001) and the TCGA datasets (P<0.001). Furthermore, the

expression of miR‑143 was significantly downregulated in the
HBV‑associated HCC samples compared with the non‑tumor
samples from the GSE22058 (P<0.001) and the TCGA datasets
(P= 0.004).
miR‑143 and miR‑145 are downregulated in HBV‑associated
HCC samples and their expression pattern is consistent
with the expression pattern of the host gene, MIR143HG. To
validate the expression profiles of miR‑143 and miR‑145 and
investigate the association with their host gene MIR143HG
(Fig. 2A), the expression of the miRNAs and the host gene
MIR143HG long non‑coding RNA (lncRNA) were examined
using RT‑qPCR in HCC and normal tissues. As presented
in Fig. 2B, miR‑143 expression was significantly decreased
in HCC tissue compared with matched distal non‑cancerous
liver tissue (NT) (HCC= 0.075 vs. NT= 0.205; P<0.05, Student's
t‑test). Furthermore, miR‑145 expression was significantly
decreased in HCC tissue when compared with NT (HCC=0.055
vs. NT= 0.232; P<0.01, Student's t‑test). No significant differences in miR‑143 and miR‑145 expression were identified
between NT and negative control samples (NC). These results
suggest that decreased miR‑143 and miR‑145 expression may
be an indicator of HBV‑associated HCC tumorigenesis.
To investigate the association between miR‑143, miR‑145
and their host gene MIR143HG, MIR143HG expression was
quantitatively assessed. As presented in Fig. 2B, MIR143HG
expression was decreased in HCC tissue compared with NT
(HCC= 0.43). Linear regression analysis indicated that the
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Figure 2. Expression patterns of MIR143HG, miR‑143 and miR‑145 in HBV‑associated HCC tissue. (A) The genomic location of MIR143HG, which encodes
miR‑143 and miR‑145 (7). (B) The expression patterns of MIR143HG, miR‑143 and miR‑145 in HBV‑associated HCC tissue (n=85), NT (n=85) and NC (n=10).
Expression levels were determined using RT‑qPCR. U6 snRNA was used for miRNA normalization. Results are presented as the mean ± standard error of
the mean. *P<0.05, **P<0.01, Student's t‑test. (C) Pearson correlation between miR‑143, miR‑145 and MIR143HG expression in HBV‑associated HCC tissue.
**
P<0.01. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NT, non‑cancerous liver tissue; NC, negative control; RT‑qPCR,
reverse transcription‑quantitative polymerase chain reaction.

expression patterns of miR‑143 and miR‑145 were consistent
with that of their host gene, MIR143HG (Fig. 2C) (miR‑145 vs.
miR‑143; P<0.001, miR‑143 vs. MIR143HG; P=0.001, miR‑145
vs. MIR143HG; P=0.009).
miR‑143 and miR‑145 expression is associated with the histo‑
logical differentiation of HBV‑associated HCC tumors. To
investigate the role of miR‑143/145 in HBV‑associated HCC,
the expression level of the miRNAs was associated with key
clinical features including tumor progression and disease
prognosis. miR‑143/145 expression was not associated with
the histological grade of the HBV‑associated HCC samples.
However, as presented in Fig. 3A, the moderately differentiated group had significantly increased miR‑143 expression
compared with the well‑differentiated group (P= 0.026).
Similarly, miR‑145 expression in the moderately differentiated
group was increased compared with the well‑differentiated
group (P= 0.012). miR‑143 and miR‑145 were significantly
overexpressed in the well‑differentiated group compared with
the negative control (P= 0.004 and P= 0.016, respectively).
The expression of the miRNAs was also associated with the
presence of metastasis, cirrhosis and complete tumor capsule
(Fig. 3B‑D); however, no statistically significant association
was detected. Similarly, no statistically significant association
was identified with age or sex (data not shown). These results
demonstrate that decreased miR‑143 and miR‑145 expression

is associated with tumor differentiation and may be a useful
indicator of poor prognosis for patients with HBV‑associated
HCC.
Serum levels of miR‑143 and miR‑145 are decreased in patients
with HBV‑associated HCC and may serve as a potential
diagnostic biomarker for HBV‑associated HCC. The results
of the present study confirmed that miR‑143 and miR‑145 were
decreased in HBV‑associated HCC tissue. To evaluate their use
in clinical applications, their expression was quantified in serum
prior to and following surgical tumor excision. As presented
in Fig. 4A, miR‑143 expression was identified to be significantly decreased in the serum of patients with HBV‑associated
HCC compared with NC (HCC= 0.06 vs. NC= 0.22; P<0.01,
independent Student's t‑test). The miR‑145 expression was also
identified to be significantly decreased in the serum of patients
with HBV‑associated HCC compared with NC (HCC=0.13 vs.
NC 0.27; P<0.01; Fig 4B).
Subsequently, the serum miR‑143 and miR‑145 RT‑qPCR
data were used to generate ROC curves for each miRNA
and determine the respective AUC. As presented in Fig. 4C
and D, the AUC of the miR‑143 ROC curve was 0.813±0.04
(mean ± standard error of the mean; 95% confidence interval,
0.735‑0.892; P<0.01) and that of the miR‑145 ROC curve was
0.852±0.039 (mean ± standard error of the mean; 95% confidence interval, 0.776‑0.928; P<0.05).
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Figure 3. Association of the miRNA expression patterns with several clinical features. (A) Tumors were characterized by pathological analysis as well,
moderately or poorly differentiated. The expression of miR‑143 and miR‑145 was determined using RT‑qPCR. U6 snRNA was used for miRNA normalization. Results are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, Student's t‑test. The HBV‑associated HCC samples were also grouped
according to the following clinical features: (B) (+/‑) Metastasis, (C) (+/‑) cirrhosis or (D) (+/‑) complete tumor capsule. No statistically significant association
was identified between these clinical features and the expression of miR‑143 and miR‑145. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

6120

ZHAO et al: miRNA-143/145 IN HBV-ASSOCIATED HCC

Figure 4. miR‑143 and miR‑145 serum levels are decreased in patients with HBV‑associated HCC and may be used to predict tumorigenesis. RT‑qPCR was
used to determine the (A) miR‑143 and (B) miR‑145 expression levels in the serum samples. miR‑143 and miR‑145 expression was significantly decreased in
the HBV‑associated HCC samples compared with NC. Results are presented as the mean ± standard error of the mean. **P<0.01, Student's t‑test. (C) The ROC
curve of serum miR‑143 expression for predicting HBV‑associated HCC tumorigenesis. The AUC was calculated to be 0.813. (D) The ROC curve of serum
miR‑145 expression for predicting HBV‑associated HCC tumorigenesis. The AUC was calculated to be 0.852. miRNA/miR, microRNA; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction; ROC, receiver‑operating characteristic; AUC,
area under the ROC curve.

Figure 5. Consolidated model for the role of miR‑143 and miR‑145 in HBV‑associated HCC. In this model, the expression of miR‑143, miR‑145 and their host
gene MIR143HG is decreased in HBV‑associated HCC tissue, and their expression is associated with the histological grade of the tumor (*P<0.05). Serum
miR‑143 and miR‑145 are decreased in patients with HBV‑associated HCC compared with NC, and may serve as potential diagnostic biomarkers to predict
tumorigenesis in patients infected with HBV. miRNA/miR, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; ROC, receiver‑operating
characteristic; AUC, area under the ROC curve; SE, standard error; CI, confidence interval.
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A threshold for each miRNA was selected to predict HCC
between patients with HBV infection. The 1.194 miR‑145
threshold identified 88.2% of patients with HBV‑associated
HCC with a comparatively lower specificity of 78%. The 0.118
miR‑143 threshold was characterized by 77.6% sensitivity and
86% specificity (Fig. 5). The results of the present study indicate
that the two miRNAs may potentially be used to predict HCC in
patients infected with HBV, with a sensitivity and specificity of
~0.80, according to the recommendations of the International
Mesothelioma Interest Group for MPM biomarkers (20).
Discussion
According to GenBank, miR‑143 and miR‑145 are encoded
by the MIR143HG gene, which is a non‑protein coding gene.
miR‑143 and miR‑145 have distinct sequences, and are located
in proximity within the MIR143HG gene. Previous studies have
demonstrated decreased miR‑143/145 expression in colonic
carcinoma, pulmonary carcinoma, esophageal carcinoma
and prostatic carcinoma (9‑12). However, their expression
profile in HCC remains controversial. A previous study
demonstrated increased expression (8), whereas decreased
expression was demonstrated in others (14,15). By contrast,
a previous study demonstrated that miR‑143/145 expression
was markedly decreased in liver tissue (7). To investigate
this further, miR‑143 and miR‑145 expression was examined
in tissue and serum samples of patients with HBV‑associated
HCC. In addition, serum miRNA data were used to evaluate
the potential clinical application of miRNAs as biomarkers for
HBV‑associated HCC.
In the present study, a model was developed to describe
the role of the miR‑143/145 cluster in HBV‑associated HCC.
As Fig. 5 indicates, the expression of miR‑143 and miR‑145
was significantly decreased in tumor tissue of patients with
HBV‑associated HCC compared with non‑tumor distal tissue.
This was particularly evident in patients with moderately and
poorly differentiated tumors. The miR‑143 and miR‑145 serum
levels were also decreased in patients with HBV‑associated
HCC in accordance with the expression profile observed in
the tumor tissues. By contrast, the expression of MIR143HG
in the serum presented no significant alteration in patients
with HBV‑associated HCC compared with NC, even though
MIR143HG was identified to be downregulated in tumor tissue.
The ROC curves generated from miR‑143 and miR‑145 serum
expression data indicated that serum miR‑143/145 expression
may be a promising biomarker for predicting tumorigenesis in
patients with HBV infection.
When examining the expression of a miRNA, its expression in tissue samples is first determined. However, when
investigating its potential clinical application, examination
of serum miRNA levels is required. HBV‑associated HCC
is a serious condition, characterized by high morbidity and
mortality, and early detection is crucial for effective surgical
excision. Since the HCC biomarkers used currently, including
serum α‑fetoprotein and the carcinoembryonic antigen, have
limited sensitivity and specificity, novel biomarkers are
required to improve the diagnosis and management of patients
with liver diseases. It has been reported that tumor‑derived
miRNAs are frequently released into the peripheral blood
circulation and remain stable, protected from RNase (21). The
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results of the present study support this hypothesis. It was
demonstrated that serum miR‑143/145 expression is consistent
with the expression in tumor tissue and the expression levels
of miR‑143/145 in patients with HBV‑associated HCC were
decreased compared with NC. Taking into consideration the
ROC curves as well, the results of the present study support the
hypothesis that serum miR‑143/145 may be a potential diagnostic biomarker for HBV‑associated HCC. Further research
is currently underway to validate this hypothesis and elucidate
the underlying molecular mechanism of miR‑143/145‑mediated
regulation of tumor biology.
Using miRNA ChIP and RT‑qPCR data, the results of the
present study confirmed that miR‑143/145 and their host gene
MIR143HG are downregulated in tumor tissue of patients
with HBV‑associated HCC. It was also demonstrated that the
expression of miR‑143/145 was associated with the histological
differentiation of HBV‑associated HCC tissues. In addition,
serum levels of miR‑143 and miR‑145 were examined and it
was demonstrated that the two miRNAs were decreased in
patients with HBV‑associated HCC compared with NC. On
the basis of the ROC curves, the results of the present study
suggest that serum miR‑143 or miR‑145 expression may be a
valuable diagnostic biomarker for predicting tumorigenesis in
patients with HBV‑associated HCC.
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